Aktis Oncology’s (AKTS) “Outperform” Rating Reaffirmed at Wedbush

Posted by Brenda Bartman on Oct 2nd, 2026

Aktis Oncology (NASDAQ:AKTS – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $35.00 price objective on the technology company’s stock. Wedbush’s target price would indicate a potential upside of 91.00% from the stock’s previous close.

A number of other research firms also recently weighed in on AKTS. Raymond James Financial initiated coverage on Aktis Oncology in a research report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price target on the stock. Oppenheimer initiated coverage on Aktis Oncology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $40.00 price target on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Aktis Oncology in a research report on Friday, September 18th. Wall Street Zen downgraded Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Finally, BMO Capital Markets initiated coverage on Aktis Oncology in a research report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.63.

Get Our Latest Analysis on AKTS

Aktis Oncology Stock Performance

Aktis Oncology stock traded down $0.20 during midday trading on Friday, hitting $18.33. 138,466 shares of the company’s stock were exchanged, compared to its average volume of 352,152. Aktis Oncology has a 52-week low of $14.72 and a 52-week high of $34.19. The stock has a 50-day moving average price of $23.55 and a two-hundred day moving average price of $22.17. The company has a market cap of $984.97 million and a P/E ratio of -22.37.

Aktis Oncology (NASDAQ:AKTS – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The business had revenue of $3.38 million during the quarter, compared to analyst estimates of $2.70 million. As a group, sell-side analysts expect that Aktis Oncology will post -1.85 earnings per share for the current year.

Insider Transactions at Aktis Oncology

In related news, Director Ken Herrmann sold 4,856 shares of the business’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $24.56, for a total transaction of $119,263.36. Following the transaction, the director owned 3,506 shares in the company, valued at $86,107.36. The trade was a 58.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. State of Wyoming bought a new stake in Aktis Oncology during the 2nd quarter valued at approximately $32,000. The Manufacturers Life Insurance Company boosted its position in Aktis Oncology by 2.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,044 shares of the technology company’s stock valued at $1,548,000 after acquiring an additional 1,051 shares in the last quarter. Bank of America Corp DE boosted its position in Aktis Oncology by 4.2% during the 2nd quarter. Bank of America Corp DE now owns 72,835 shares of the technology company’s stock valued at $2,347,000 after acquiring an additional 2,909 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Aktis Oncology by 14.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 49,250 shares of the technology company’s stock valued at $1,587,000 after acquiring an additional 6,349 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in Aktis Oncology by 49.3% during the 2nd quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock valued at $678,000 after acquiring an additional 6,942 shares in the last quarter. Hedge funds and other institutional investors own 28.84% of the company’s stock.

Aktis Oncology Company Profile

(Get Free Report)

Aktis Oncology, Inc is a clinical-stage biopharmaceutical company developing targeted alpha therapies for the treatment of cancer. Its research is focused on creating therapies designed to selectively deliver alpha-particle radiation to tumor cells while limiting exposure to surrounding healthy tissue.

The company’s platform uses proprietary tumor-targeting molecules, including engineered miniproteins, to bind specific targets found on cancer cells and transport radioactive payloads to tumors.